Senti Biosciences, Inc. (SNTI)

Market Cap	100.87M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	43.42M
EPS (ttm)	-3.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,938
Open	2.37
Previous Close	2.3
Day's Range	2.22 - 2.38
52-Week Range	1.2 - 10.35
Beta	n/a
Analysts	Buy
Price Target	9.01 (+300.4%)
Earnings Date	Nov 21, 2022

About SNTI

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells...

• Industry: Biotechnology
• Founded: 2016
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: SNTI

Full Company Profile

Financial Performance

In 2021, SNTI's revenue was $2.76 million, an increase of 387.81% compared to the previous year's $566,000. Losses were -$55.32 million, 178.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for SNTI stock is "Buy." The 12-month stock price forecast is 9.01, which is an increase of 300.44% from the latest price.

Price Target

$9.01

(300.44% upside)

Analyst Consensus: Buy

Stock Forecasts